Release details

2017-02-17 08:00 CET
  • Print
  • Share Share

Publishing of Nexstim Plc 2016 Full Year Results

Company announcement, Helsinki, 17 February 2017, at 9 am

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system, will announce its full year results for the year ended 31 December 2016 in the morning of Monday 28 February 2017.

A conference call for analysts, investors and media will take place at 16:00 Finnish time (EET) on Monday 28 February 2017, hosted by Martin Jamieson, Chairman of the Board and CEO, and Mikko Karvinen, CFO, who will present the financial and operational results followed by a Q&A session.

The dial-in numbers for the conference call are:
Finland: +358 (0) 800 914672
Sweden: +46 (0) 20 089 6388
UK: +44 (0) 20 3003 2666
US: + 1 866 966 5335
Standard International: +44 (0) 20 3003 2666

The call Password is Nexstim

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by contacting:

Nexstim                                                                +447715163942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com
                                                                                                                                                                                                        
UB Securities Oy (Certified Adviser)           +358 (0)9 2538 0246

Citigate Dewe Rogerson                        +44 (0)207 2821066
Katja Stout                                        katja.stout@citigatedr.co.uk

About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

HUG#2079580